CTCF and neoplasm: These findings demonstrate that circARAP2 holds promise as a prospective biomarker and therapeutic target for sMICA-induced NK cell desensitization, and also highlight the circARAP2/CTCF-PRC2/RAB5A axis as a novel mechanism for regulating NK cell desensitization and tumor immune evasion.